Payment & Shipping Terms:
|Appearance:||White Powder||Function:||Bodybuilding Or Cuting|
Sunifiram (DM-235) is a piperazine derived ampakine drug which acts as a positive allosteric
modulator of AMPA receptors, and has nootropic effects in animal studies with significantly
higher potency than piracetam. A number of related compounds are known, the best known
being unifiram (DM-232)
This enhancement by sunifiram is associated with an increase inphosphorylation of AMPAR through activation of protein kinase II(CaMKII) and an increase in phosphorylation of NMDAR through activation of protein kinase C α (PKCα). More specifically, sunifiram stimulates the glycine-binding site of NMDAR with concomitant PKCαactivation through Src kinase. Enhancement of PKCα activity triggers to potentiate hippocampal LTP through CaMKII activation. Sunifiram improves cognitive deficits via CaM kinase II andprotein kinase C activation.
2. Specification (Manufacturer supply directly)
Product Name Sunifiram (DM-235)
Molecular Formul C14H18N2O2
Molecular Weight 246.304
CAS No. 314728-85-3
Melting point 94.5°C-95.5°C
Appearance Off-white to white crystalline powder
1.Sunifiram activates AMPA-mediated neurotransmission.
2.Enhancing LTP in a bell-shaped dose-response relationship.
3.Sunifiram aids in the release of acetylcholine in the cerebral cortex.
4. Packing &Storage
25kg/drum or as per customer's requirement
Store in a well-closed container away from moisture
2 years if sealed and store away from direct sun light.
Within 7 working days after order confirmation
|AICAR||2627-69-2||acts by entering nucleoside pools, significantly increasing levels of adenosine
during periods of ATP breakdown
|MK2866||841205-47-8||medical prescription for prevention of cachexia, atrophy, and sarcopenia and
for Hormone or Testoserone Replacement Therapy.
for the treatment of frailty in the elderly
|LGD-4033||1165910-22-4||pharmacological profile similar to that of enobosarm, Ostarine,MK-2866|
|GW1516||317318-70-0||For obesity, diabetes, dyslipidemia and cardiovascular disease|
|Andarine(S4)||401900-40-0||partial agonist, intended mainly for treatment of benign prostatic hypertrophy|
|SR9009||1379686-30-2||under development at The Scripps Research Institute (TSRI),
increases the level of metabolic activity in skeletal muscles of mice
|RAD140||1182367-47-0||New generation for gaining mass and cutting edges|
|YK11||431579-34-9||YK11: a SARM and myostatin inhibitor in one|